Understanding how cancer treatment drugs can harm the kidneys
Off target mechanisms of kinase inhibitor toxicities
This study is looking into how certain cancer drugs, called kinase inhibitors, might accidentally harm your kidneys, and it aims to find out why some people have kidney problems while using these treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11023117 on NIH RePORTER |
What this research studies
This research investigates the unintended effects of kinase inhibitors, which are drugs used in cancer treatment, on kidney health. It focuses on how these drugs can inhibit not only their intended targets but also other proteins, leading to kidney damage. By studying the mechanisms behind these toxicities, particularly the role of a specific enzyme called ferrochelatase, the research aims to uncover why some patients experience kidney issues when treated with these medications. The approach includes both laboratory experiments and analysis of patient data to better understand these side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients who are receiving kinase inhibitor therapies and may be experiencing kidney-related side effects.
Not a fit: Patients who are not undergoing treatment with kinase inhibitors or do not have kidney issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments with fewer kidney-related side effects for patients.
How similar studies have performed: Previous research has shown that understanding off-target effects of cancer therapies can lead to improved treatment safety, indicating potential for success in this area.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Pabla, Navjot — Ohio State University
- Study coordinator: Pabla, Navjot
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.